Dual targeting CDK4/6 and CDK7 augments tumor response and anti-tumor immunity in breast cancer models. Kim S, Son E, Park HR, Kim M, et al. J Clin Invest 2025 Aug 12:e188839. doi: 10.1172/JCI188839.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kim S, Son E, Park HR, Kim M, et al. Dual targeting CDK4/6 and CDK7 augments tumor response and anti-tumor immunity in breast cancer models. J Clin Invest 2025 Aug 12:e188839. doi: 10.1172/JCI188839.
PMID: 40794455